Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia

被引:0
作者
Siddiqui, Naveed Ali [1 ]
Ishaque, Imran [2 ]
Rahat, Yousra [3 ]
Akhtar, Naheed [4 ]
Tehreem, Umaya [3 ]
Javed, Rafia [3 ]
Ali, Rayyan [3 ]
机构
[1] United Med & Dent Coll, Dept Biochem, Karachi, Pakistan
[2] United Med & Dent Coll, Dept Anat, Karachi, Pakistan
[3] United Med & Dent Coll, Karachi, Pakistan
[4] Karachi Inst Med Sceinces, Dept Anat, Karachi, Pakistan
来源
ANNALS ABBASI SHAHEED HOSPITAL & KARACHI MEDICAL & DENTAL COLLEGE | 2021年 / 26卷 / 02期
关键词
Urea; Creatinine; Diabetic dyslipidemia; HMG-CoA reductase inhibitor; Coronary heart disease; CARDIOVASCULAR-DISEASE; FAILURE SECONDARY; LIPID PROFILE; RHABDOMYOLYSIS; SIMVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the adverse effects of HMG CoA reductase inhibitor (statin) and garlic (Allium sativum) on renal function in diabetic dyslipidemic patients. Methods: This clinical trial was conducted at Surgeon Munawar Memorial Hospital, Karachi from 1st March 2019 to 30th August 2019. Total of 60 patients of 30-70 years of age with abnormal lipid profile were enrolled for this study after a written consent. The study was conducted to assess the side effects of statin (20 mg/day) and garlic (300 mg/day) in diabetic dyslipidemia patients. The study period consisted of six months. Blood pressure, body weight and height of subjects were assessed. The patient answered the questionnaire on health complaints, smoking, social role, drug usage, family history and dietary pattern. The initial inclusion criteria of the patient were 1) Age between 30-70 years old of either sex, 2) Patients with diabetic dyslipidemia. The exclusion criteria were 1) Pregnancy or lactation, 2) Patients with liver diseases, 3) Patients with renal diseases. Detailed medical history and physical examination of all patients were carried out. Results: This study included 60 patients with an abnormal lipid profile of age 30-70 years. International statin product (20 mg/day) and local garlic product (300 mg/day) for 08 weeks were used for oral administration in patients. Urea and creatinine levels in the serum of diabetic dyslipidemic patients were measured before and after treatment with an international statin (20 mg/day) and a local garlic product (300 mg/day). Conclusion: According to the findings of this study, statins increase the serum level of urea and creatinine while has no effect on urea and creatinine serum level.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [41] THERAPEUTIC EFFICACY OF THE HMG-COA-REDUCTASE INHIBITOR PRAVASTATIN IN HYPERLIPOPROTEINEMIA TYPE-II
    SAXENHOFER, H
    WEIDMANN, P
    RIESEN, WF
    BERETTAPICCOLI, C
    FRAGIACOMO, C
    WUNDERLIN, R
    NOSEDA, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (02) : 101 - 105
  • [42] SCREENING FUNGI FOR THE PRODUCTION OF AN INHIBITOR OF HMG COA REDUCTASE - PRODUCTION OF MEVINOLIN BY THE FUNGI OF THE GENUS PLEUROTUS
    GUNDECIMERMAN, N
    FRIEDRICH, J
    CIMERMAN, A
    BENICKI, N
    FEMS MICROBIOLOGY LETTERS, 1993, 111 (2-3) : 203 - 206
  • [43] Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase
    Fujino, H
    Nakai, D
    Nakagomi, R
    Saito, M
    Tokui, T
    Kojima, J
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2004, 54 (07): : 382 - 388
  • [44] Do HMG-CoA reductase inhibitors improve kidney function? The saga continues
    Campese, Vito M.
    Ku, Elaine
    Bigazzi, Roberto
    Bianchi, Stefano
    JOURNAL OF NEPHROLOGY, 2011, 24 (05) : 550 - 553
  • [45] HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
    Seliger, SL
    Weiss, NS
    Gillen, DL
    Kestenbaum, B
    Ball, A
    Sherrard, DJ
    Stehman-Breen, CO
    KIDNEY INTERNATIONAL, 2002, 61 (01) : 297 - 304
  • [46] Positive pleiotropic effects of HMG-CoA reduction inhibitor on vitiligo
    Noël M.
    Gagné C.
    Bergeron J.
    Jobin J.
    Poirier P.
    Lipids in Health and Disease, 3 (1)
  • [47] Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer
    Schointuch, Monica N.
    Gilliam, Timothy P.
    Stine, Jessica E.
    Han, Xiaoyun
    Zhou, Chunxiao
    Gehrig, Paola A.
    Kim, Kenneth
    Bae-Jump, Victoria L.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 346 - 355
  • [48] The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
    Stine, Jessica E.
    Guo, Hui
    Sheng, Xiugui
    Han, Xiaoyun
    Schointuch, Monica N.
    Gilliam, Timothy P.
    Gehrig, Paola A.
    Zhou, Chunxiao
    Bae-Jump, Victoria L.
    ONCOTARGET, 2016, 7 (01) : 946 - 960
  • [49] HMG-CoA Reductase Inhibitor Regulates Endothelial Progenitor Function Through the Phosphatidylinositol 3′-Kinase/AKT Signal Transduction Pathway
    Xiaohong Li
    Biao Xu
    Applied Biochemistry and Biotechnology, 2009, 157 : 545 - 553
  • [50] HEPATIC AND NONHEPATIC STEROL SYNTHESIS AND TISSUE DISTRIBUTION FOLLOWING ADMINISTRATION OF A LIVER SELECTIVE HMG-COA REDUCTASE INHIBITOR, CI-981 - COMPARISON WITH SELECTED HMG-COA REDUCTASE INHIBITORS
    BOCAN, TMA
    FERGUSON, E
    MCNALLY, W
    UHLENDORF, PD
    MUELLER, SB
    DEHART, P
    SLISKOVIC, DR
    ROTH, BD
    KRAUSE, BR
    NEWTON, RS
    BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1123 (02) : 133 - 144